Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Resource Profile: NonComparativeEvidence - Examples

Page standards status: Trial-use Maturity Level: 1

Examples for the non-comparative-evidence Profile.

Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
Medication Adherence at 12 weeks for Candesartan in NCT03640312
Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312